Quick Answer
Cocrystal Pharma, Inc. reported Cash and Equivalents of $26.35 million for fiscal year 2023.
Cocrystal Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $26.35M | -29.1% |
| 2022 | $37.14M | -36.7% |
| 2021 | $58.70M | +77.8% |
| 2020 | $33.01M | +345.0% |
| 2019 | $7.42M | +891.7% |
| 2017 | $748.0K | -79.3% |
| 2016 | $3.60M | -61.1% |
| 2015 | $9.28M | +133.7% |
| 2014 | $3.97M | +283.9% |
| 2013 | $1.03M | -78.1% |
| 2012 | $4.72M | +13236.9% |
| 2011 | $35.4K | -85.9% |
| 2010 | $251.5K | -57.2% |
| 2009 | $587.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $18.14M | -44.0% | -16.9% |
| March 31, 2024 | $21.84M | -35.7% | -17.1% |
| December 31, 2023 | $26.35M | -29.1% | -11.4% |
| September 30, 2023 | $29.74M | -29.3% | -8.3% |
| June 30, 2023 | $32.42M | -36.5% | -4.6% |
| March 31, 2023 | $33.98M | -38.0% | -8.5% |
| December 31, 2022 | $37.14M | -36.7% | -11.7% |
| September 30, 2022 | $42.06M | -31.8% | -17.6% |
- Cocrystal Pharma, Inc. showed a decrease of -29.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2023 period, Cocrystal Pharma, Inc.’s cash and equivalents has grown by 4386.3% (from $587.4 thousand to $26.35 million).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 28, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: